Eli Lilly and Company
NASDAQ: LLYKey stats
Price chart
About Eli Lilly and Company
Pharmaceuticals
Company profile
- IPO date
- Jul 9, 1970
- Website
- www.lilly.com
Healthcare peers
How LLY compares to other large companies in the same sector.
| Company | Price | Today | Market cap | P/E |
|---|---|---|---|---|
 JNJ Johnson & Johnson | $238.48 | -1.17% | $574.36B | 21.43 |
 ABBV AbbVie Inc. | $207.96 | -2.09% | $367.80B | 87.03 |
 MRK Merck & Co. | $121.44 | -1.01% | $300.20B | 16.45 |
 UNH UnitedHealth Group | $304.35 | -0.83% | $276.23B | 22.91 |
 PFE Pfizer Inc. | $26.93 | -1.07% | $153.07B | 19.70 |
Wall Street analyst ratings
DollarScout analysis
Editorial, not advice. See our methodology.
Bull case
Eli Lilly's strength lies in its innovative pharmaceutical contributions, especially in diabetes and immunology treatments. Drugs like Trulicity and Taltz show strong sales potential, tapping into growing global health concerns. Lilly's research pipeline with drugs focused on solving major health issues like Alzheimer's and cancer reflects a promising future. The company maintains a competitive edge through its substantial R&D investments and strong patent protection. Despite a hefty market cap, the stock enjoys analyst confidence with a strong buy consensus, indicating trust in its future prospects.
Bear case
LLY's high P/E ratio of 43.01 reflects premium investor expectations, which could pose a risk if earnings growth doesn't keep pace. While innovative, Lilly faces stiff competition from big pharma players in key segments like diabetes, where cost pressures and market saturation could limit pricing power. Additionally, the company’s modest dividend yield of 0.6066% may not attract income-focused investors. Regulatory risks and potential setbacks in the development of its new pipelines could also impact performance.
Who should buy LLY
LLY is well-suited for investors with a long-term growth focus who are comfortable with the high valuation multiple and modest dividend yield. Ideal for those interested in the healthcare sector's innovation frontier, willing to accept moderate volatility for potential strong returns from product breakthroughs.
Key risks
- High P/E ratio indicates growth expectations must be met to justify valuation. - Competitive pressures in pharmaceuticals, especially for diabetes and immunology. - Regulatory risks potentially affecting drug approvals and sales. - Dependence on successful advancements in clinical trials for future growth.
Where to buy LLY
Open an account with a broker we've reviewed and start trading Eli Lilly and Company today.
Want to practice first? Try the free Stock Trading Simulator with $100,000 virtual cash.
Recent LLY news
And it's not too late to get in on the action.
Eli Lilly secures FDA approval for Foundayo, an oral GLP-1 therapy targeting obesity with significant advantages. Learn why LLY stock is a buy.
Diversified hands-off retirement portfolio: 12 funds (ETFs/CEFs/mutual) targeting 6% yield + 6% dividend growth. Read the full list of picks here.
Amazon Pharmacy has entered the weight loss medication market with Eli Lilly’s new GLP-1 drug, offering same day delivery and raising competitive pressure on Hims & Hers Health (NYSE:HIMS). Hims & Hers is developing an AI driven product approach that may support new non prescription solutions and product rollouts later this year. The company is also contending with regulatory scrutiny and margin pressures as its weight loss offerings become a more important part of its business mix. Hims &...
Companies have long lamented Europe's fragmented capital markets, single-market adoption on pricing and clinical trials, and uneven reimbursement policies.
Cheap semaglutide generics have launched in India following local loss of exclusivity for Novo Nordisk, triggering rapid price cuts and market share shifts in GLP-1 treatments. Dozens of low cost versions are pressuring pricing for obesity and diabetes drugs, prompting Novo Nordisk to lower prices on its own GLP-1 brands. Eli Lilly’s GLP-1 franchise is also seeing volume effects as patients switch to generics, offering an early look at how global patent expiries could affect GLP-1...
Eli Lilly and Company (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) reported quarterly results in early February, and the gap between them has widened significantly. Lilly’s tirzepatide franchise is accelerating. Novo is cutting jobs, warning of a sales decline, and leaning on a newly launched pill to stabilize its position. Tirzepatide Pulls Away. Semaglutide Faces the ... Eli Lilly vs. Novo Nordisk: The Obesity Drug Race Has a New Leader
Eli Lilly launches oral GLP-1 pill Foundayo, pairing low-cost access with Amazon and GoodRx partnerships to challenge rivals in the fast-growing obesity market.
Disclaimer: The information on this page is provided for informational and educational purposes only and should not be considered financial, investment, or trading advice. DollarScout does not recommend buying or selling any specific security. Stock data may be delayed. Past performance is not indicative of future results. Always do your own research and consult a licensed financial advisor before making investment decisions.